neural stem cells
Don’t see what you’re looking for? Use the search box on MDA’s Quest magazine.
Neuralstem is seeking permission to evaluate efficacy in its phase 1 safety trial, as well as to increase the dosage and number of trial participants
Posted on Wednesday, May 16, 2012 - 04:39, By: Amy Madsen
The biotherapeutics company Neuralstem is seeking to amend the design of its ongoing phase 1 stem cell trial in amyotrophic lateral sclerosis (ALS) to include evaluations of efficacy (how well the therapy works).
Although the phase 1 trial isn’t currently designed to evaluate efficacy, early...
Posted on Thursday, September 1, 2011 - 10:35, By: ALSN Staff
Disease 'in a dish' is a new tool for studying ALS
An MDA-supported research team has created a human cellular model of ALS using cells taken from people with the ALS8 subtype of the disease, a familial (inherited) form of ALS (amyotrophic lateral sclerosis) caused by mutations in the VAPB gene.
‘Smooth progress' reported in Neuralstem's human clinical trial of neural stem cells; FDA permission sought to proceed to cervical injections
Posted on Friday, June 17, 2011 - 11:21, By: Amy Madsen
Maryland biotherapeutics company Neuralstem has announced favorable results from the first part of a phase 1 trial to test the safety of its experimental spinal cord stem cell treatment in ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease).